Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. [electronic resource]
Producer: 20200324Description: 755-760 p. digitalISSN:- 1537-453X
- Adenocarcinoma -- diagnostic imaging
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- CA-125 Antigen -- blood
- Camptothecin -- adverse effects
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Fluorouracil -- adverse effects
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Leucovorin -- adverse effects
- Magnetic Resonance Imaging -- methods
- Male
- Membrane Proteins -- blood
- Middle Aged
- Nelfinavir -- adverse effects
- Neoadjuvant Therapy -- methods
- Neoplasm Invasiveness -- pathology
- Organoplatinum Compounds -- adverse effects
- Pancreatic Neoplasms -- diagnostic imaging
- Pancreaticoduodenectomy -- methods
- Proportional Hazards Models
- Radiosurgery -- methods
- Risk Assessment
- Survival Analysis
- Time Factors
- Tomography, X-Ray Computed -- methods
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.